Global provider of Outsourced Clinical Research
Joined February 2009
- Tweets 11,490
- Following 10,471
- Followers 15,547
- Likes 4,439
8,000 Photos and videos
ICON’s near-term, long-term and #netzero targets have been validated by #SBTi. In 2024 we decreased Scope 3 emissions 7.56% compared to 2022. Read more: ow.ly/viYB50VZTWN
1
1
7
1,824
ICON Biotech is sponsoring #CTOEC26, taking place 30 June – 1 July at the Boston Marriott Burlington, MA. Visit us at Booth 18 to learn how ICON supports oncology programs across the full clinical development lifecycle. ow.ly/Tkz250YUsLT
52
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest #clinicaltrial regulatory updates current. ow.ly/bHue50Z6Em9
#regulatoryintelligence #regulatorycompliance #biotech #pharma #FoodandDrugAdministration #europeanmedicinesagency
42
ICON joins #ACRO’s Good Clinical Podcast on advancing rare disease research through AI and patient trust.
We share where AI is already making a difference and where careful application still matters in small, complex datasets.
ow.ly/EOSw50Z7TbQ
48
Recent changes to biosimilar regulatory approaches will reduce the time and resources required to develop biosimilars, but they also represent a fundamental shift for development strategy. Learn about the implications of recent regulatory guidance ow.ly/GVRP50Z7TzM
2
94
#FattyLiverDay is June 11. With cases expected to triple to 357M by 2030, advancing fatty liver disease research is critical. Discover how ICON supports clients in reaching their hepatology clinical development goals to improve liver health worldwide. ow.ly/4y5550Z33Vh
2
61
From clinical development to post-marketing surveillance, global safety requirements are complex and constantly changing.
ICON’s regulatory intelligence service provides the clarity needed to manage that complexity with confidence.
Watch the video: ow.ly/C83r50Z9hx7
1
41
Updated #biologics guidance signals a shift toward risk based #viralsafety, modern analytics and clearer clearance strategies. ICON’s John Muganga shares practical insights for manufacturers navigating these #regulatory changes. Read more in PharmTech. ow.ly/KENg50Z7n62
2
81
Artificial intelligence is a powerful tool for enhancing trial accuracy, predictive modeling, and patient safety in vaccine innovation. Read the article to learn how AI is driving the next phase of clinical research: ow.ly/GLMU50Z4A7H
52
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest #clinicaltrial regulatory updates current. ow.ly/bHue50Z6Em9
#regulatoryintelligence #regulatorycompliance #biotech #pharma #FoodandDrugAdministration #europeanmedicinesagency
1
77
From complex trial designs to vast patient data, vaccine R&D faces significant operational hurdles. Discover how integrating AI can help developers solve legacy challenges in our article: ow.ly/7PAq50Z4A4A
101
Biosimilar regulations are evolving. New guidance could remove certain clinical study requirements and simplify global trials. Explore the implications: ow.ly/ju5l50YYSsk
#biosimilars #regulatoryaffairs #biopharma #clinicalresearch
2
155
ICON is attending #CYTO 2026 in West Palm Beach, FL on 6–10 June. Visit us at booth #715 to connect with our flow cytometry experts and learn how our globally aligned capabilities support innovative and complex clinical trials. ow.ly/tMFU50YQTUI
1
91
Vaccine development has traditionally taken years, but a technology-driven mindset is completely redefining the timeline. Explore how artificial intelligence is streamlining workflows and accelerating delivery in our article: ow.ly/rWCI50Z4zZh
1
64
High interest does not equal smooth enrolment in psychedelic trials. Expect tighter criteria, more screen failures, and added complexity. A few practical considerations for sponsors: ow.ly/PlKE50YXWKJ
46
As #biosimilardevelopment shifts toward analytical comparability over clinical confirmation, CMC strategy is more critical than ever.
In PharmTech, Venkat Reddy Sunkara and Kim Salgado explore impacts on formulation, timelines and #regulatory success. ow.ly/KF9r50YYPPt
1
59
Visit us at ASCO, booth #35093 to learn about ICON’s purpose built technology suite supports AI powered site identification, streamlined activation, contract drafting and site collaboration, helping sponsors move forward with efficiency and confidence. ow.ly/S5Gb50YKPcV
348
Psychedelic trials show promise but bring operational risk. ICON’s support of a global programme across 150 sites and 12 countries show what’s possible when complexity is planned for from day one. Learn more: ow.ly/abe050YXWzL
#MentalHealthAwarenessMonth
53
Meet the ICON team on 9 – 10 June at #OCTUK26 in London. We're gearing up for impactful discussions on advancing clinical trials. 13th Annual Outsourcing in Clinical Trials UK & Ireland 2026 - Arena International. ow.ly/2YPg50YBetu
78
Advancing #dermatology research: ICON co-authored the ViSENPsO® scale, a validated, user-friendly visually guided tool for evaluating nail #psoriasis severity to help improve consistency across clinical studies. ow.ly/nbRf50YYUMt
#ClinicalResearch #HealthcareInnovation
81
Honoured to be recognised by IMAPAC at ABEA 2026 for Site Innovation.
This award reflects the dedication of our APAC teams and our shared mission to accelerate clinical development for patients worldwide. ow.ly/IPF450YKPu1
#ClinicalResearch #Innovation #APAC
104